1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
1859 has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in February 2022.
1859's investors include Vertical Venture Partners, OMX Ventures, FusionX Ventures, Northpond Ventures.
1859 is headquartered in San Diego, United States.
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
1859 is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"1859 — Funding & Investors." VCBacked, February 7, 2022, https://www.vcbacked.co/company/1859. Accessed August 13, 2026.
VCBacked. (2022). 1859 — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/1859
{{cite web |title=1859 — Funding & Investors |url=https://www.vcbacked.co/company/1859 |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated